key: cord-0996693-juff617c
authors: Lopez-Leon, Sandra; Wegman-Ostrosky, Talia; Perelman, Carol; Sepulveda, Rosalinda; Rebolledo, Paulina; Cuapio, Angelica; Villapol, Sonia
title: More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis
date: 2021-03-01
journal: Res Sq
DOI: 10.21203/rs.3.rs-266574/v1
sha: 6bee35260bfb9b73c05383e337e2fb4f46e6d0ec
doc_id: 996693
cord_uid: juff617c

Background. COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers. This systematic review and meta-analysis aims to identify studies assessing long-term effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. Methods . LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. All articles with original data for detecting long-term COVID-19 published before 1 (st) of January 2021 and with a minimum of 100 patients were included. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. Heterogeneity was assessed using I (2) statistics. This systematic review followed Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) guidelines, although the study protocol was not registered. Results. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. The follow-up time ranged from 14 to 110 days post-viral infection. The age of the study participants ranged between 17 and 87 years. It was estimated that 80% (95% CI 65-92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). All meta-analyses showed medium (n=2) to high heterogeneity (n=13). Conclusions . In order to have a better understanding, future studies need to stratify by sex, age, previous comorbidities, the severity of COVID-19 (ranging from asymptomatic to severe), and duration of each symptom. From the clinical perspective, multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in China in December 2019. Since then, more than 90 million people worldwide have been infected after a year, and over 2 million people have died from the coronavirus disease 2019 (COVID-19)(1). Although unprecedented efforts from the scienti c and medical community have been directed to sequence, diagnose, treat, and prevent COVID-19, individuals' lasting effects after the acute phase of the disease are yet to be revealed.

To date, there is no established term to coin the slow and persistent condition in individuals with lasting sequelae of COVID-19. Different authors have used the terms "Long-COVID-19", "Long Haulers", "Post-acute COVID-19", "Persistent COVID-19 Symptoms", "Post COVID-19 manifestations", "Longterm COVID-19 effects", "Post COVID-19 syndrome", among others. In the absence of an agreed de nition, we convened for this review to refer to "Long-term effects of COVID-19". Symptoms, signs, or abnormal clinical parameters persisting two or more weeks after COVID-19 onset that do not return to a healthy baseline can potentially be considered long-term effects of the disease (2) . Although such alteration is mostly reported in severe and critical disease survivors, the lasting effects also occur in individuals with a mild infection who did not require hospitalization (3) . It has not yet been established if sex, gender, age, ethnicity, underlying health conditions, viral dose, or progression of COVID-19 signi cantly affect the risk of developing long-term effects of COVID-19 (4) .

Since rst reported, there has been a vast amount of social media patient groups, polls, comments, and scienti c articles aiming to describe the chronicity of COVID-19. In parallel, hundreds of scienti c publications, including cohorts studying speci c effects of the disease and lists of case reports, have been described (5) . However, a broad overview of all the possible longstanding effects of COVID-19 is still needed.

The aim of our study was to perform a systematic review and meta-analysis of peer-reviewed studies to estimate the incidence of all the symptoms, signs, or abnormal laboratory parameters extending beyond the acute phase of COVID-19 reported to date.

The search's objective was to identify peer-reviewed human studies in English that reported symptoms, signs, or laboratory parameters of patients at a post-COVID-19 stage (assessed two weeks or more after initial symptoms) in cohorts of COVID-19 patients. Only studies with a minimum of 100 patients were included.

The databases used to identify the studies were LitCOVID (6) (PubMed and Medline) and Embase. Studies were included if they were published before January 1st 2021. The search terms used for both searches were: COVID long* OR haulers OR post OR chronic OR term OR complications OR recurrent OR lingering OR convalescent OR convalescence. Given that LitCOVID includes all articles from MedLine, in the search in Embase we excluded the articles from MedLine and those not related to COVID-19. All types of studies, including randomized controlled trials, cohorts, and cross-sectional studies, were analyzed only when the cases (numerator) were part of a COVID-19 cohort (denominator). Titles, abstracts, and full texts of articles were independently screened by two authors (SLL and TWO). The complete article was reviewed in case of difference of opinion on the inclusion based on title or abstract. Disagreement on the inclusion of a full-text article was discussed with all the authors. The exclusion criteria were: (1) not written in English; (2) have less than 100 patients included in the study. The systematic review followed the Preferred reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) guidelines (7, 8) .

Data were extracted by 4 authors (AC, PR, RS, SV) and QCed by two authors (TWO, CP). The descriptive variables extracted were country, setting, follow-up time, the severity of COVID-19, sample size, mean age and percentage of gender, outcomes, and names used to describe the Long-term effects of COVID-19.

All the diseases, disorders, symptoms, signs, and laboratory parameters reported total numbers or percentages were included. When two-time points were reported in the study, the outcomes assessed after the most extended follow-up were used.

For effects reported only in a single study, the prevalence was estimated by dividing the number of patients with each symptom by the total number of COVID-19 patients in the sample multiplied by 100 to estimate the percentage. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence, which uses a double arcsine transformation (9) .

Prevalence with 95% Con dence Intervals (CI) was presented.

Given the heterogeneity expected, a random-effects model was used. Heterogeneity was assessed using the I 2 statistics. Values of 25%, 50%, and 75% for I 2 represented low, medium, and high heterogeneity. Sensitivity analyses were performed to assess the contribution of each study.

Each study's quality was assessed and described using the MetaXL Guidelines, which is speci c to evaluate the quality of studies assessing incidence and prevalence.

A description of what was considered is found in supplement Table 1 . The number of patient cohorts that were followed up in the studies ranged from 102 to 44,799.

Adults ranging from 17-87 years of age were included. There were no studies with overlapping samples. A couple of studies reported that fatigue was more common in female, and one study reported that post activity polypnea and alopecia were more common in female (3, 10) . The rest of the studies did not stratify their results by age or sex.

Regarding the quality of the studies, all had a score of 8 or more. The general characteristics of the studies are shown in Table 1 . Different authors have used the terms "Post-acute COVID-19", "Long COVID-19", "Persistent COVID-19 Symptoms", "Chronic COVID-19", "Post COVID-19 manifestations", "Long-term COVID-19 effects", "Post COVID-19 syndrome", "Ongoing COVID-19," "long term sequelae", or "Long-haulers" as synonyms (Table 2) . We identi ed a total of 55 long-term effects associated with COVID-19 in the literature reviewed ( Table 3) . Most of the effects correspond to clinical symptoms such as fatigue, headache, joint pain, anosmia, ageusia, etc. Diseases such as stroke and diabetes mellitus were also present. Measurable parameters included 6 elevated laboratory parameters, i.e., interleukin-6 (IL-6), procalcitonin, serum ferritin, C-reactive protein (CRP), N-terminal (NT)-pro hormone BNP (NT-proBNP), and D-dimer. Abnormal chest XRay/computed tomography (CT) was also identi ed (Fig. 2) . Table 2 presents the prevalence of all the effects that were reported. It was possible to perform 21 meta-analyses, for the rest the prevalence was estimated using 1 cohort. The meta-analysis of the studies (n = 7) that included an estimate for one symptom or more reported that 80% (95% CI 65-92) of the patients with COVID-19 have long-term symptoms. Fig. 2 ). An abnormal chest XRay/CT was observed in 34% (95% CI 27-42) of the patients. Markers reported to be elevated were D-dimer (20%, 95% CI 6-39), NT-proBNP (11%, 95% CI 6-17) C-reactive protein (8%, 95% CI 5-12), serum ferritin (8% 95% CI 4-14), procalcitonin (4% 95% CI 2-9) and IL-6 (3% 95% CI% 1-7) ( Table 2 , Fig. 2 ).

Other symptoms were related to lung disease (cough, chest discomfort, reduced pulmonary diffusing capacity, sleep apnea, and pulmonary brosis), cardiovascular (arrhythmias, myocarditis), neurological (dementia, depression, anxiety, attention disorder, obsessive-compulsive disorders), and others were unspeci c such as hair loss, tinnitus, and night sweat ( Table 2 , Fig. 2 ). Two meta-analyses showed low heterogeneity (I 2 < 25%), two medium heterogeneity, and the high rest heterogeneity (I 2 > 75%).

One study was excluded because it did not provide a denominator, and therefore it was not possible to estimate the prevalence (11) . In such a study, the authors performed a survey in a Facebook group of patients who previously had COVID-19 and compared the symptoms of those hospitalized with mild to moderate symptoms. They concluded that both groups had symptoms after three months of having COVID-19. Symptoms that were not mentioned in any of the articles we studied include sudden loss of body weight, ear pain, eye problems, sneezing, cold nose, burning feeling in the trachea, dizziness, heart palpitations, pain/ burning feeling in the lungs, pain between the shoulder blades, Sicca syndrome, vertigo, body aches, and confusion (2, 12) .

The recovery from COVID-19 should be more developed than checking for hospital discharge or testing negative for SARS-CoV-2 or positive for antibodies (13) . This systematic review and meta-analysis shows that 80% (95% CI 65-92) of individuals with a con rmed COVID-19 diagnosis continue to have at least one overall effect beyond two weeks following acute infection. In total, 55 effects, including symptoms, signs, and laboratory parameters, were identi ed, with fatigue, anosmia, lung dysfunction, abnormal chest XRay/CT, and neurological disorders being the most common (Table 1 , Fig. 2) . Most of the symptoms were similar to the symptomatology developed during the acute phase of COVID-19. However, there is a possibility that there are other effects that have not yet been identi ed. In the following paragraphs, we will discuss the most common symptoms to illustrate how complex each one can be. However, further studies are needed to understand each symptom separately and in conjunction with the other symptoms. The ve most common effects were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%).

Fatigue (58%) is the most common symptom of long and acute COVID-19 (14) . It is present even after 100 days of the rst symptom of acute COVID-19 (3, 14) . There are syndromes such as acute respiratory distress syndrome (ARDS), in which it has been observed that after a year, more than twothirds of patients reported clinically signi cant fatigue symptoms (15) . The symptoms observed in post-COVID-19 patients, resemble in part the chronic fatigue syndrome (CFS), which includes the presence of severe incapacitating fatigue, pain, neurocognitive disability, compromised sleep, symptoms suggestive of autonomic dysfunction, and worsening of global symptoms following minor increases in physical and/or cognitive activity (16) (17) (18) (19) (20) . Currently, myalgic encephalomyelitis (ME) or CFS is a complex and controversial clinical condition without established causative factors, and 90% of ME/CFS has not been diagnosed (21) . Possible causes of CFS include viruses, immune dysfunction, endocrine-metabolic dysfunction, and neuropsychiatric factors. The infectious agents related to CFS have been Epstein-Barr virus, cytomegalovirus, enterovirus and herpesvirus (22) . It is tempting to speculate that SARS-CoV-2 can be added to the viral agents' list causing ME/CFS.

Several neuropsychiatric symptoms have been reported, headache (44%), attention disorder (27%), and anosmia (21%). There are other symptoms reported, which were not included in the publications, including brain fog and neuropathy (23, 24) . The etiology of neuropsychiatric symptoms in COVID-19 patients is complex and multifactorial. They could be related to the direct effect of the infection, cerebrovascular disease (including hypercoagulation)(25), physiological compromise (hypoxia), side effects of medications, and social aspects of having a potentially fatal illness (26) .

Adults have a double risk of being newly diagnosed with a psychiatric disorder after the COVID-19 diagnosis (26) , and the most common psychiatric conditions presented were anxiety disorders, insomnia, and dementia. Sleep disturbances might contribute to the presentation of psychiatric disorders (27) . Prompt diagnosis and intervention of any neuropsychiatric care is recommended for all patients recovering from COVID-19. An increase in mental health attention models in hospitals and communities is needed during and after the COVID-19 pandemic. Hair loss after COVID-19 could be considered as telogen e uvium, de ned by diffuse hair loss after an important systemic stressor or infection, and it is caused because of premature follicular transitions from active growth phase (anagen) to resting phase (telogen). It is a self-limiting condition that lasts approximately 3 months, but it could cause emotional distress (28) .

Dyspnea and cough were found in 24% and 19% of patients, respectively ( Table 2 , Fig. 2 ). In addition, abnormalities in CT lung scans persisted in 35% of patients even after 60-100 days from the initial presentation. In a follow-up study conducted in China among non-critical cases of hospitalized patients with COVID-19, radiographic changes persisted in nearly two-thirds of patients 90 days after discharge (29) . Although most of the available studies do not include baseline pulmonary dysfunction or radiographic abnormalities, ndings indicate improvement or resolution of abnormal CT ndings. Previous data from recovered patients with other viral pneumonia (30, 31) , also found residual radiographic changes. Abnormalities in pulmonary function, such as decreased diffusion capacity for carbon monoxide, were present among 10% of patients in this meta-analysis. Although these ndings are not as high as compared to other available studies of survivors with COVID-19 or SARS, where the estimate of lung dysfunction is 53% and 28% respectively (32, 33) , the reasons behind these differences could be distinct follow-up periods, de nitions of pulmonary dysfunction, or characteristics of the patient population. Nevertheless, residual radiographic ndings or lung function abnormalities require additional investigation on their clinical relevance and long-term consequences.

The immune-mediated tissue damage in COVID-19 involves cellular and humoral responses, but the immunity to SARS-CoV-2 and the protection to reinfection or a nal viral (29, 34) clearance is unknown. Also, the reason why some patients experience long-term symptoms after COVID-19 is (33, 35, 36) . In addition, MERS survivors showed pulmonary brosis (33%) (37) . Regarding psychiatric symptoms, a study reported high levels of depression, anxiety, and post-traumatic stress disorder (PTSD) (26) in the long term in patients previously infected with other coronaviruses.

To assure that future healthcare providers, researchers, and educators recognize the effects of long-term COVID19 that are sex-and age-speci c related, it is of high importance to classify the groups according to such variables to make better decisions about prevention, diagnosis and disease management.

Limitations of this systematic review and meta-analyses include the small sample size for some outcomes, which makes it di cult to generalize these results to the general population. The variation in the de nition of some outcomes and markers and the possibility of bias. For example, several studies that used a self-reported questionnaire could result in reporting bias. In addition, the studies were very heterogeneous, mainly due to the followup time references and the mixture of patients who had moderate and severe COVID-19. All of the studies assessed had performed their internal prede nition of symptoms, and therefore there is the possibility that important outcomes were not reported. Another limitation is that, given that COVID-19 is a new disease, it is not possible to determine how long these effects will last. In order to decrease heterogeneity and have a better understanding of the long-term effects of COVID-19, there is a need for studies to stratify by age, previous comorbidities, the severity of COVID-19 (including asymptomatic), as well as the duration of each symptom. To determine whether these long-term effects either complicate previous diseases or are a continuation of COVID-19, there is a need for prospective cohort studies. The baseline characteristics should be well established.

There is a need to standardize biological measures such as peripheral blood markers of genetic, in ammatory, immune, and metabolic function to compare studies. Besides studying pre-de ned symptoms and markers, an open question should be included. Proper documentation in medical charts by health care providers and the exibility and collaboration from the patients to report their symptoms are of equal importance.

More evidence and research from multi-disciplinary teams are crucial to understanding the causes, mechanisms, and risks to develop preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address the after-COVID-19 care.

From the clinical point of view, physicians should be aware of the symptoms, signs, and biomarkers present in patients previously affected by COVID-19 to promptly assess, identify and halt long COVID-19 progression, minimize the risk of chronic effects and help reestablish pre-COVID-19 health.

Management of all these effects requires further understanding to design individualized, dynamic cross-sectoral interventions in Post-COVID clinics with multiple specialties, including graded exercise, physical therapy, continuous checkups, and cognitive behavioral therapy when required (38, 39) . 

Ethical Approval and Consent to participate.

"Not applicable" Consent for publication.

"Not applicable".

Availability of supporting data.

All data relevant to the study are included in the article or uploaded as supplementary information.

Competing interests. The authors are solely responsible for all content, and funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare that they have no competing interests. SLL is an employee of Novartis Pharmaceutical Company; the statements presented in the paper do not necessarily represent the position of the company. The remaining authors have no competing interests to declare.

Funding. This work was supported by grant R21NS106640 from National Institute for Neurological Disorders and Stroke (NINDS), and funds from Houston Methodist Research Institute, Houston, TX.

Authors' contributions. TWO and CP performed the statistical analysis. SLL, TWO, CP, RS, PR, and SV did the literature search, collected the data, wrote the manuscript and make edits. SLL and SV were mainly responsible for interpretation of the data and preparing the nal version. SV did gures. All 

This is a list of supplementary les associated with this preprint. Click to download.

Coronavirus Pandemic (COVID-19)

Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States

Persistent Poor Health Post-COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity

Post-COVID-19 global health strategies: the need for an interdisciplinary approach

Management of post-acute covid-19 in primary care

LitCovid: an open database of COVID-19 literature

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P)

Meta-analysis of prevalence

Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study

Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?

Persistent Symptoms in Patients After Acute COVID-19

COVID-19 sickness, not just positive tests and deaths

Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection

Fatigue Symptoms During the First Year Following ARDS

COVID-19 and chronic fatigue syndrome: Is the worst yet to come? Med Hypotheses

Could Cognitive Behavioural Therapy Be an Effective Treatment for Long COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome

Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae

Long-Haul COVID

Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Rede ning an Illness

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism

Finding the 'right' GP: a qualitative study of the experiences of people with long-COVID

Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians

Cerebral venous thrombosis and SARS-CoV-2 infection: a systematic review and meta-analysis

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

Insomnia in the Italian Population During Covid-19 Outbreak: A Snapshot on One Major Risk Factor for Depression and Anxiety

Telogen e uvium: a sequela of COVID-19

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors

Emerging. H7N9 in uenza A (novel reassortant avian-origin) pneumonia: radiologic ndings

Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

Immunity and immunopathology to viruses: what decides the outcome?

Cytokine release syndrome in severe COVID-19

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease

The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS

Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial

authors provided critical feedback and contributed to the nal manuscript. Acknowledgements."Not applicable".